Dyadic (DYAI) Q3 2026 earnings review
Dyadic's grant revenue drops fast, and first product sales stay tiny
Dyadic, a biotechnology company that brews animal-free proteins from engineered fungi, saw its grant funding dry up before product sales could replace it. Third-quarter revenue fell 61% from a year ago to $449,000 as work under its Gates Foundation and vaccine grants wound down. President and operating chief Joe Hazelton touted the company's first direct sales of lab proteins, yet admitted the amounts were immaterial and that customer testing is taking longer than planned.
| Revenue | $449K -61% from a year ago |
|---|---|
| Grant revenue | $276K -67% from last quarter |
| Net loss, excluding warrant gain | $1.90M by our math, vs $1.98M a year ago |
| Unrestricted cash and investments | $4.58M by our math, after issuing 3.65M shares |
⚖️ Verdict: 🔴 Bearish
The story got worse because the expected drop in grant revenue arrived while commercial sales are still near zero. To keep cash at $6.05 million—or $4.58 million excluding restricted funds, by our math—Dyadic expanded its share count by 10% in one quarter and took on new warrant liabilities. One bright spot: dairy-enzyme partner Inzymes made a first commercial sale in October, triggering a $225,000 milestone check for the fourth quarter.
The question now is whether partner launches and licensing talks can bring in enough cash to fund the business without constant share dilution. Either partner royalties and upfront deals step up in coming quarters, or overhead costs of $1.45 million a quarter force another dilutive raise. Fourth-quarter milestone receipts and any first royalty check from albumin partner Proliant will tell.
🐂 Bull Case
Partner Launches Trigger Fourth-Quarter Milestone Cash
Dyadic uses its Dapibus and C1 microbial platforms, which are engineered fungi that brew animal-free proteins, to develop products that partners manufacture and sell. Because the biotech group lacks its own sales force, it relies on these partners for upfront fees, milestone checks and future profit shares.
In October, dairy-enzyme partner Inzymes made its first commercial sale of camel chymosin, a cheese-making protein brewed with Dapibus. That sale earned Dyadic a $225,000 milestone payment for the fourth quarter. Meanwhile, distributor Integrated Biotherapeutics launched six research proteins, and partner Proliant planned two new versions of AlbuFree, its lab-grown human albumin.
What to watch: fourth-quarter license and milestone revenue, plus any first profit-share check from Proliant's February launch. A reading above the $225,000 Inzymes check would show that partner launches are starting to pay recurring royalties.
Gates Antibody Program Reaches Animal Testing
Under a $3.1 million grant from the Gates Foundation, the Florida company uses its C1 fungus to brew low-cost monoclonal antibodies against respiratory syncytial virus (RSV) and malaria. Dyadic wants this non-dilutive work to prove its fungal system can make complex drugs faster and cheaper than standard animal cells.
In seven-day fermentation runs, the team reached output yields of 12.1 grams per liter for the RSV antibody and 13.2 grams per liter for malaria. In October, the Gates Medical Research Institute started animal trials "to evaluate the pharmacokinetics of the C1-produced RSV and malaria antibodies through direct, head-to-head comparisons" with standard versions.
What to watch: the animal trial readout in the first quarter of 2027. Matching the standard antibodies would support a new grant or licensing deal to replace the current funding.
🐻 Bear Case
Grant Funding Dropped by Two Thirds
Dyadic gets most of its revenue from research grants funded by the Gates Foundation and the Coalition for Epidemic Preparedness Innovations (CEPI). Because the Gates cash was already received in full by mid-year and the CEPI award had little room left, our prior analysis flagged that grant revenue would soon run down.
That drop arrived this quarter. Grant revenue fell 66% from a year ago and 67% from the second quarter to $276,372, which the company blamed on "lower activities under the Gates Foundation and CEPI grants". Research and development revenue from customer projects also fell 54% to $162,318 as earlier collaborations ended.
- Total third-quarter revenue: $449,101, down 61.4% from a year ago
- Grant revenue: $276,372, down from $837,252 last quarter
- Deferred research obligations on the balance sheet: $1.58 million, up 1.3% from last quarter
What to watch: fourth-quarter grant revenue and any new grant award disclosures. Another quarter near $275,000 would confirm the CEPI program has wound down, leaving a permanent hole in the top line.
First Direct Sales Brought Almost No Revenue
"While early sales remain modest and evaluation timelines are longer than anticipated, we are seeing increased sampling requests-particularly for transferrin-as we convert initial qualifications into potential business," president and operating chief Joe Hazelton said. Transferrin and DNase I are animal-free proteins used to grow cells and clean lab samples.
Dyadic announced its first direct commercial sales of those two proteins this quarter. Yet the protein maker admitted that "initial sales were not material in amount" and still did not add a product sales line to its income statement. Total license and milestone revenue was just $10,411.
This gap matters because Dyadic rebranded a year ago to become a commercial supplier, and its partner royalty terms remain undisclosed. Meanwhile, customer sampling for its alpha-lactalbumin nutrition protein, previously targeted for mid-2026, was still described only as advancing collaboration activities.
What to watch: whether the full-year report breaks out a separate product sales or royalty revenue line. Keeping product sales combined or unquantified would show that customer sampling is still not turning into commercial orders.
Share and Warrant Issuance Kept Cash Afloat
Dyadic ended June with $4.79 million in total cash and warned of "substantial doubt about our ability to continue as a going concern for the 12 months following November 12, 2026". Hazelton said the team is evaluating "financing alternatives and other opportunities aimed at strengthening our balance sheet".
Total cash and investments rose to $6.05 million in September, or $4.58 million by our math after stripping out $1.46 million of restricted cash. To raise that cash, Dyadic issued 3.65 million new common shares by our math, lifting outstanding shares 10% in one quarter to 40.09 million, and added an $813,424 warrant liability.
A $545,527 non-cash accounting gain on those warrants trimmed the reported net loss to $1.36 million; without it, the net loss was $1.90 million by our math. Stockholders' deficit widened to $2.58 million, and $5.05 million of convertible debt—41% held by related parties—still sits ahead of shareholders.
What to watch: the financing footnote in the quarterly filing for the exact terms of the share and warrant issuance. At the current operating loss pace, unrestricted cash covers less than three quarters.
Overhead Costs Swallowed Three Times the Revenue
General and administrative expenses—the overhead cost of running the company, legal bills and business development—stood at $1.45 million in the third quarter. While that figure dipped 2.1% from a year ago on lower legal fees, outside business development and other costs climbed by $146,500.
Because revenue shrank so sharply, overhead jumped to 323% of revenue, up 196 percentage points from a year ago by our math. At the same time, Dyadic cut its own research and development spending by 24.8% to $429,945 (up 47 percentage points of revenue by our math) by reducing active internal research projects.
What to watch: general and administrative spending in the fourth quarter. Unless Dyadic cuts outside consulting and overhead below $1.45 million a quarter, new milestone checks will be consumed by corporate expenses.
💲 Other KPIs
Unpaid bills and accrued liabilities rose sharply this quarter, helping preserve cash. Accounts payable jumped 86.5% from the second quarter and 26.0% from a year ago by our math to $1.52 million, while accrued expenses held at $1.39 million. Together they now equal 64% of the company's unrestricted cash.
Money owed by customers and grant partners climbed 16.9% from last quarter and 66.2% from a year ago by our math, even as quarterly revenue dropped by more than half. Receivables now equal more than three times third-quarter revenue, tying up working capital until those bills are collected.
Gross profit—revenue minus the direct cost of carrying out grant and research projects—returned to a positive 16.5% margin by our math, up 4.4 percentage points from a year ago and recovering from a $23,027 gross loss in the second quarter, as grant project costs fell 65.5% alongside lower grant activity.
❓ Key Questions
How much did the first direct protein sales bring in?
Dyadic recorded its first direct commercial sales of transferrin and DNase I but called them immaterial and disclosed no dollar figure. Investors need the exact revenue and order backlog to judge commercial demand.
What were the terms of the third-quarter financing?
Outstanding shares rose by 3.65 million and a new $813,424 warrant liability appeared on the balance sheet, with $388,702 of issuance costs. Management has not disclosed the price per share or warrant exercise terms in the release.
How much funding remains under the CEPI vaccine grant?
Quarterly grant revenue dropped from $837,252 to $276,372 as CEPI and Gates work slowed. Knowing the exact unbilled dollar balance left on the CEPI contract will tell whether grant revenue has hit its floor.
When will Proliant albumin sales produce royalties?
Proliant launched AlbuFree DX in February 2026 and is planning two new versions, yet Dyadic reported only $10,411 in total license and milestone revenue this quarter. The profit-share percentage and payment lag remain undisclosed.